Business
Cerus Corporation to Participate in the TD Cowen 45th Annual Health Care Conference
CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) announced today that members of Cerus’ management are scheduled to present at the TD
About this update from Cerus Corporation
CONCORD, Calif. --(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) announced today that members of Cerus’ management are scheduled to present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5 , at 11:10 a.m. EST . A live webcast of the fireside chat will be available via the following link . A replay will be available for 90 days after the event. ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California , the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S. , the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex ), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is in late-stage clinical development. For more information about Cerus , visit www.cerus.com and follow us on LinkedIn. INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation . View source version on businesswire.com : https://www.businesswire.com/news/home/20250219621903/en/ Noopur Liffick NBL LifeSci Advisory 925-298-2338 Source: Cerus Corporation